

Supporting Information

**Cross-Linked (R)-(+)-Lipoic Acid Nanoparticles with
Prodrug Loading for Synergistic Cancer Therapy**

Fan Yang, Yun Chen, Jing Zhang, Chunyan Liao, and Shiyong Zhang**

National Engineering Research Centre for Biomaterials and College of Chemistry, Sichuan University,
29 Wangjiang Road, Chengdu 610064, China.

*To whom correspondence should be addressed: liao_cy2020@126.com, szhang@scu.edu.cn.


General Method

Routine NMR spectra were obtained on a Bruker AV II-400. The ^1H NMR chemical shifts were measured relative to CDCl_3 as the internal reference (CDCl_3 : δ 7.26 ppm). The ^{13}C NMR chemical shifts were given using CDCl_3 as the internal standard (CDCl_3 : δ 77.5 ppm). Mass spectrometry was performed on a Waters Q-ToF premier instrument. The particle sizes were measured with a Dynamic Light Scattering (DLS) Analyzer (Malvern Zetasizer Nano ZS90). Transmission electron microscopy (TEM) studies were carried out using a Tecnai G2F20S-TWIN instrument, operating at 120 kV. The TEM specimens were prepared by gently placing a carbon-coated copper grid on the surface of the sample. The TEM grid was then removed, stained with an aqueous solution of 2% phosphotungstic acid, dried for 0.5 h at room temperature, and then subjected to TEM observation. Gel permeation chromatography (GPC) was performed on an HLC-8320GPC instrument using N,N-Dimethylformamide (DMF) as the mobile phase at a flow rate of 1 mL/min at 40 °C, and the molecular weights were reported relative to polystyrene (PS) standards. The *in vitro* release experiment of camptothecin (CPT) was performed in sink (AHYQ SHA-C) at 37 °C. The CPT standard curve was analyzed at 254 nm by high performance liquid chromatography (HPLC, Agilent 1260 LC, Zorbax C18 column 4.6 ×150 mm) with 45% of buffer A and 55% of buffer B within 10 min and flow rate 1.0 mL/min (buffer A: deionized water, buffer B: Methanol). The cell viability was measured using a Thermo Varioskan Flash microplate reader (USA). Cell cycle assay, cell apoptosis assay and cell uptake were measured by flow cytometry (Becton Dickinson, USA). The Western Blotting Detection was measured by a ChemiDoc XR+UV illuminator (Bio-Rad, USA). Mean density of the bands for Bcl-2 and Caspase-3 in HT29 cells was analyzed using the Image J and the β -actin was used as the loading control. The tissue slices were imaged using inverted optical microscopy (Leica DMI4000B, Germany).

Chemicals: Unless otherwise noted, all reagents were obtained from commercial suppliers and used without further purification. All solvents for reactions were freshly distilled prior to use. Deionized water was used in all aqueous experiments.

Synthesis

Scheme S1 Synthesis of compound 1



Compound 1. Camptothecin (100 mg, 0.287 mmol), 3-(methylthio) propionic acid (69 mg, 0.575 mmol), *N*-(3-(dimethylamino)-propyl)-*N*-ethylcarbodiimide hydrochloride (EDCI) (165 mg, 0.86 mmol), 4-dimethylaminopyridine (DMAP) (3.5 mg, 0.029 mmol) were dissolved in 30 mL of dichloromethane (CH₂Cl₂). The mixture was stirred at room temperature for 48 h, and then chloroform (30 mL) was added. The organic phase was washed with water (20 mL), saturated NaHCO₃ (10 mL) and brine (20 mL), and then dried over anhydrous MgSO₄. The solvent was removed under vacuum and the residue was purified by column chromatography with CH₂Cl₂ – CH₃ OH (30:1) to give **1** as a pale yellow solid (64 mg, 55%).

¹H NMR (400 MHz, CDCl₃) δ 8.44 (s, 1H), 8.28 (d, *J* = 8.5 Hz, 1H), 7.96 (d, *J* = 8.1 Hz, 1H), 7.86 (t, *J* = 7.7 Hz, 1H), 7.69 (t, *J* = 7.5 Hz, 1H), 7.42 (s, 1H), 5.69 (d, *J* = 17.2 Hz, 1H), 5.40 (d, *J* = 17.2 Hz, 1H), 5.36 – 5.18 (m, 2H), 2.86 (dd, *J* = 10.3, 4.3 Hz, 2H), 2.78 (dd, *J* = 13.5, 7.2 Hz, 2H), 2.25 (ddd, *J* = 28.7, 14.5, 7.4 Hz, 2H), 2.14 (s, 3H), 1.00 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 171.03, 167.37, 157.30, 151.95, 148.17, 145.91, 145.67, 131.80, 131.05, 129.11, 128.59, 128.25, 128.21, 120.45, 96.97, 77.24, 76.18, 67.05, 49.98, 34.17, 31.76, 28.59, 15.57, 7.61. High resolution ESI-MS (*m/z*): calcd for C₂₄H₂₂N₂O₅SH⁺ [M+H]⁺ 450.1322, found: 451.1339, calcd for C₂₄H₂₂N₂O₅SNa⁺ [M+Na]⁺ 473.1142, found: 473.1134, calcd for C₂₄H₂₂N₂O₅SK⁺ [M+K]⁺ 489.1025, found: 489.1041.




Fig. 1S ¹H NMR spectra of sodium lipoic acid aqueous solution in D₂O before a) and after b) cross-linking.




Fig. 2S GPC curve of the cLANs formed by sodium lipoic acid.




Fig. 3S *In vitro* biocompatibility of cLANs. a) Hemolysis rate of cLANs and the corresponding hemolysis pictures (inset) at different concentrations. b) Hemagglutination assay of cLANs at different concentrations. Saline was used as control. Saline and distilled water were used as negative and positive controls, respectively.




Fig. 4S Histological analysis of mice tissues treated with various treatments. Representative histological microphotographs of heart, liver, spleen, lung and kidney of HT29 tumor bearing nude mice treated with saline, cLANs, CPT, Pro-CPT, [Pro-CPT+cLANs] and Pro-CPT@cLANs, respectively (n = 5).




Fig. 5S Cell viability of CPT and Pro-CPT against L929 cells after incubation for 48 h at 37 °C with a series of concentrations.




Fig. 6S Cell viability of CPT@cLANs and Pro-CPT@cLANs against L929 cells after incubation for 48 h at 37 °C with a series of concentrations.




Fig. 7S ¹H NMR of Compound 1.




Fig. 8S ¹³C NMR of Compound 1.




Fig. 9S MS Spectrum of Compound 1.

Table S1 Zeta potential of the cLANs in PBS buffer and in culture medium of RPMI-1640 containing 10% FBS.

pH	Zeta Potential (mV)	
	PBS	RPMI-1640
7.4	-13.2	-6.7
6.5	-8.9	-3.4